Faruqi & Faruqi, LLP reminds investors of the August 10, 2026 deadline to seek lead plaintiff in a securities class action against ADMA Biologics. The lawsuit alleges the company made false statements and failed to disclose a related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. A March 24, 2026 Culper Research report claimed ADMA induced a distributor to stock excess ASCENIV, causing the stock to drop 29% over two trading days. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 may be eligible to participate.
ADMA Biologics IncSecurities class action lawsuit alleging false statements, channel stuffing, and inadequate internal controls.